CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine

被引：17

作者：

Capi, Matilde ^{[1
]}

De Angelis, Valerio ^{[2
]}

De Bernardini, Donatella ^{[1
]}

De Luca, Ottavia ^{[3
]}

Cipolla, Fabiola ^{[2
]}

Lionetto, Luana ^{[1
]}

Simmaco, Maurizio ^{[1
,3
,4
]}

Martelletti, Paolo ^{[2
]}

机构：

[1] St Andrea Univ Hosp, Mass Spectrometry Unit, Lab Clin Biochem, I-00185 Rome, Italy

[2] Sapienza Univ Rome, Dept Clin & Mol Med, I-00185 Rome, Italy

[3] St Andrea Univ Hosp, Adv Mol Diagnost Unit, Lab Clin Biochem, I-00185 Rome, Italy

[4] Sapienza Univ, Dept Neurosci Mental Hlth & Sensory Organs NESMOS, I-00185 Rome, Italy

来源：

JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 07期

关键词：

migraine; CGRP; therapy; gepants; ditans; antagonism; CGRP receptor; GENE-RELATED PEPTIDE; MONOCLONAL-ANTIBODIES; SAFETY PROFILE; LASMIDITAN;

D O I：

10.3390/jcm10071429

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecules of the CGRP receptor ("gepants") and of a new class of medications called "Ditans". This review presents the data from clinical trials reporting the efficacy, safety, and tolerability of the new drugs used in the treatment of migraines. Evidences show that therapeutic approaches targeted to CGRP have the potential to transform the clinical management of migraine, even though its appropriate place has yet to be determined with accuracy.

引用

页数：17

共 50 条

[11] The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials
Peer C. Tfelt-Hansen
Jes Olesen
The Journal of Headache and Pain, 2012, 13 : 271 - 275
[12] Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review
Moreno-Ajona, David
Chan, Calvin
Villar-Martinez, Maria Dolores
Goadsby, Peter J.
HEADACHE, 2019, 59 : 3 - 19
[13] The 5-HT1F receptor as the target of ditans in migraine - from bench to bedside
Mitsikostas, Dimos D.
Waeber, Christian
Sanchez-del-Rio, Margarita
Raffaelli, Bianca
Ashina, Hakan
van den Brink, Antoinette Maassen
Andreou, Anna
Pozo-Rosich, Patricia
Rapoport, Alan
Ashina, Messoud
Moskowitz, Michael A.
NATURE REVIEWS NEUROLOGY, 2023, 19 (08) : 489 - 505
[14] Targeted 5-HT1F Therapies for Migraine
Marta Vila-Pueyo
Neurotherapeutics, 2018, 15 : 291 - 303
[15] Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine
Nichols, Paula L.
Brand, Jonathan
Briggs, Michael
D'Angeli, Mathilde
Farge, Jennifer
Garland, Stephen L.
Goldsmith, Paul
Hutchings, Rio
Kilford, Ian
Li, Ho Y.
MacPherson, David
Nimmo, Fiona
Sanderson, Francis Dominic
Sehmi, Sanjeet
Shuker, Nicola
Skidmore, John
Stott, Michael
Sweeting, Jennifer
Tajuddin, Hasmi
Takle, Andrew K.
Trani, Giancarlo
Wall, Ian D.
Ward, Robert
Wilson, David M.
Witty, David
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (04) : 1368 - 1372
[16] Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT1F receptor agonists for migraine therapy
Jin, Chuanfei
Yi, Chao
Zhong, Wenhe
Xue, Yaping
Chen, Kangzhi
Deng, Kang
Wang, Zusheng
Wang, Tao
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 225
[17] Caprolactams as potent CGRP receptor antagonists for the treatment of migraine
Shaw, Anthony W.
Paone, Daniel V.
Nguyen, Diem N.
Stump, Craig A.
Burgey, Christopher S.
Mosser, Scott D.
Salvatore, Christopher A.
Rutledge, Ruth Z.
Kane, Stefanie A.
Koblan, Kenneth S.
Graham, Samuel L.
Vacca, Joeseph P.
Williams, Theresa M.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (17) : 4795 - 4798
[18] Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis
Min Hou
Haiyan Xing
Chen Li
Xianfeng Wang
Dongmei Deng
Juan Li
Pan Zhang
Jianhong Chen
The Journal of Headache and Pain, 2020, 21
[19] Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis
Hou, Min
Xing, Haiyan
Li, Chen
Wang, Xianfeng
Deng, Dongmei
Li, Juan
Zhang, Pan
Chen, Jianhong
JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01)
[20] CGRP receptor antagonists: an expanding drug class for acute migraine?
Negro, Andrea
Lionetto, Luana
Simmaco, Maurizio
Martelletti, Paolo
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (06) : 807 - 818

← 1 2 3 4 5 →